On Nov. 22, 2021, Pfizer announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age.

The updated findings from the companiesﾒ pivotal Phase 3 trial showed that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ﾵg per dose) was 100% effective against COVID-19, measured seven days through over four months after the second dose.